Abcellera Biologics Inc. Stock
Price
Target price
€4.26
€4.26
1.860%
0.078
1.860%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Abcellera Biologics Inc. Stock
Abcellera Biologics Inc. gained 1.860% today.
So far the community has only identified positive things for Abcellera Biologics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Abcellera Biologics Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
AbCellera (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL635, an investigational antibody